# Fileset

[4-APL Materials 12(1) 010601.pdf](https://mdr.nims.go.jp/filesets/f1aa5f01-b519-4d5c-8151-a8d391a94b45/download)

## Creator

Mahmoud M. Selim, [Sherif El-Safty](https://orcid.org/0000-0001-5992-9744), Abdelouahed Tounsi, [Mohamed Shenashen](https://orcid.org/0000-0003-1592-5877)

## Rights

[Creative Commons BY Attribution 4.0 International](https://creativecommons.org/licenses/by/4.0/)

## Other metadata

[A review of magnetic nanoparticles used in nanomedicine](https://mdr.nims.go.jp/datasets/eba9ac4c-0ef7-45c0-b26e-412659ace494)

## Fulltext

A review of magnetic nanoparticles used in nanomedicineViewOnlineExportCitationCrossMarkREVIEW ARTICLE |  JANUARY 31 2024A review of magnetic nanoparticles used in nanomedicineMahmoud M. Selim   ; Sherif El-Safty  ; Abdelouahed Tounsi  ; Mohamed Shenashen APL Mater. 12, 010601 (2024)https://doi.org/10.1063/5.0191034 31 January 2024 17:27:13https://pubs.aip.org/aip/apm/article/12/1/010601/3261403/A-review-of-magnetic-nanoparticles-used-inhttps://pubs.aip.org/aip/apm/article/12/1/010601/3261403/A-review-of-magnetic-nanoparticles-used-in?pdfCoverIconEvent=citehttps://pubs.aip.org/aip/apm/article/12/1/010601/3261403/A-review-of-magnetic-nanoparticles-used-in?pdfCoverIconEvent=crossmarkjavascript:;https://orcid.org/0000-0002-9727-4520javascript:;https://orcid.org/0000-0001-5992-9744javascript:;https://orcid.org/0000-0002-5601-3228javascript:;https://orcid.org/0000-0003-1592-5877javascript:;https://doi.org/10.1063/5.0191034https://servedbyadbutler.com/redirect.spark?MID=176720&plid=2299798&setID=592934&channelID=0&CID=845202&banID=521658143&PID=0&textadID=0&tc=1&scheduleID=2219892&adSize=1640x440&data_keys=%7B%22%22%3A%22%22%7D&matches=%5B%22inurl%3A%5C%2Fapm%22%5D&mt=1706722033731789&spr=1&referrer=http%3A%2F%2Fpubs.aip.org%2Faip%2Fapm%2Farticle-pdf%2Fdoi%2F10.1063%2F5.0191034%2F19331196%2F010601_1_5.0191034.pdf&hc=4148feb865f91c79c774519edbc50d61faca7cec&location=APL Materials REVIEW pubs.aip.org/aip/apmA review of magnetic nanoparticlesused in nanomedicineCite as: APL Mater. 12, 010601 (2024); doi: 10.1063/5.0191034Submitted: 11 December 2023 • Accepted: 8 January 2024 •Published Online: 31 January 2024Mahmoud M. Selim,1,a) Sherif El-Safty,2 Abdelouahed Tounsi,3 and Mohamed Shenashen4AFFILIATIONS1 Department of Mathematics, College of Science and Humanities, Prince Sattam Bin Abdulaziz University, P.O. Box 710,Al-Kharj 16273, Saudi Arabia2National Institute for Materials Science (NIMS), 1-2-1 Sengen, Ibaraki-ken, Tsukuba-Shi 305-0047, Japan3Yonsei Frontier Lab, Yonsei University, Seoul, South Korea4Department of Petrochemical, Egyptian Petroleum Research Institute (EPRI), Nasr City, 11727 Cairo, Egypta)Author to whom correspondence should be addressed: m.selim@psau.edu.saABSTRACTThe ability to manipulate magnetic nanoparticles with external magnetic fields and their compatibility with biological systems make themversatile tools in the field of nanomedicine. Recently, the integration of various nanotechnologies with biomedical science, pharmacology,and clinical practice has led to the emergence of the discipline of nanomedicine. Owing to the special qualities of nanoparticles and relatednanostructures, their uses in controlled drug and gene delivery, imaging, medical diagnostics, monitoring therapeutic outcomes, and support-ing medical interventions offer a fresh approach to difficult problems in difficult areas like the treatment of cancer or crippling neurologicaldiseases. The potential for multi-functionality and advanced targeting tactics in nanoparticle products exists. It may maximize the effective-ness of current anticancer drugs by enhancing the pharmacodynamic and pharmacokinetic characteristics of conventional therapies. Thesenanometer-sized substances’ distinctive electrical, magnetic, and optical characteristics have opened up a wide range of biological uses. Asthey may be used in healthcare situations due to their bioactivity, iron-oxide-based magnetic nanoparticles, in particular, have been shown tobe incredibly useful deep-tissue scanning tools. In addition to having a broader operating temperature range, smaller size, reduced toxicity,easier processing, and less cost of production, newer nanoparticles (MNPs) also offer other benefits. MNPs offer a lot of promise for use inclinical settings because of a variety of exceptional and distinctive chemical and biological features. Modern targeting techniques and nanopar-ticles studied in clinical trials are included in this review. It highlights the difficulties in applying nanomedicine items and transferring themfrom the laboratory to the clinical environment. It also addresses topics of nanoparticle design that might create new clinical applicationsfor nanomedicine items. Magnetic nanoparticles used in nanomedicine offer several novel and promising features that make them valuabletools for various applications. When utilized in nanomedicine, magnetic nanoparticles have a number of exciting new properties that makethem useful instruments for a range of uses. Drug delivery, hyperthermia therapy, magnetic resonance imaging contrast agents, diagnosticimaging and monitoring, theranostic applications, biocompatibility and biodegradability, remote control and manipulation, and responsivenanoparticles are the main factors that add to their novelty. In general, the amalgamation of nanoscale characteristics and magnetic propertiespresents a multitude of opportunities for inventive medical applications, offering focused, effective, and least intrusive approaches to diagno-sis and treatment. The sector is still investigating novel ways to increase the safety and efficacy of magnetic nanoparticles in nanomedicine.The purpose of this article is to provide basic details about magnetic nanoparticles and the characteristics of these particles in biomedicalapplications. The features of these nanoparticles in medication delivery and their numerous uses have received extra focus in the study. Itseeks to summarize current advancements in MNPs for medical applications and examine the possibilities of MNPs in tumor therapeuticapplications, in addition to future study opportunities.© 2024 Author(s). All article content, except where otherwise noted, is licensed under a Creative Commons Attribution (CC BY) license(http://creativecommons.org/licenses/by/4.0/). https://doi.org/10.1063/5.0191034APL Mater. 12, 010601 (2024); doi: 10.1063/5.0191034 12, 010601-1© Author(s) 2024 31 January 2024 17:27:13https://pubs.aip.org/aip/apmhttps://doi.org/10.1063/5.0191034https://pubs.aip.org/action/showCitFormats?type=show&doi=10.1063/5.0191034https://crossmark.crossref.org/dialog/?doi=10.1063/5.0191034&domain=pdf&date_stamp=2024-January-31https://doi.org/10.1063/5.0191034https://orcid.org/0000-0002-9727-4520https://orcid.org/0000-0001-5992-9744https://orcid.org/0000-0002-5601-3228https://orcid.org/0000-0003-1592-5877mailto:m.selim@psau.edu.sahttps://doi.org/10.1063/5.0191034APL Materials REVIEW pubs.aip.org/aip/apmI. INTRODUCTIONMagnetic nanoparticles are being actively researched and uti-lized in the field of nanomedicine for a variety of applications. Thesenanoparticles are typically made of magnetic materials like ironoxide or iron–platinum and are often coated with biocompatiblematerials to enhance their stability and biocompatibility. Using anexternal magnetic field, therapeutic medications or molecules maybe loaded onto magnetic nanoparticles and directed to precise tar-get areas within the body. Treatment effectiveness can be increasedand negative effects can be decreased with this tailored medicationadministration. In addition, when placed in an alternating magneticfield, magnetic nanoparticles may produce heat. This characteristicis used in magnetic hyperthermia treatment, which involves heat-ing these nanoparticles selectively in the presence of an outsidemagnetic field in order to cure or kill cancer cells. Furthermore, mag-netic nanoparticles can be employed in several imaging modalities,including magnetic resonance imaging (MRI), as contrast agents.They improve the visibility of particular tissues or structures, whichhelps with illness monitoring and early detection. Better imaging oftissues and organs is possible with the use of magnetic nanoparti-cles, which can increase the sensitivity and resolution of MRI images.Magnetic nanoparticles are a promising treatment option for bloodpurification in diseases such as sepsis since they may be used toextract toxins, infections, or certain biomolecules from the circula-tion. In cancer treatment, magnetic nanoparticles can be used forboth drug delivery and hyperthermia therapy, making it possible tospecifically target and treat cancer cells while minimizing damage tohealthy tissues. Target cells can receive therapeutic genes throughthe use of magnetic nanoparticles as gene therapy carriers. To iden-tify certain proteins, infections, or environmental contaminants,magnetic nanoparticles are employed in biosensors and diagnosticequipment. Magnetic nanoparticles have been explored for applica-tions in the nervous system, such as crossing the blood–brain barrierand delivering drugs to specific regions of the brain. Althoughindications only arise at aggressive cancer levels, initial-stage can-cer detection is of significant interest and difficult to prevent itsspread. Very precise, quick, durable, non-invasive, or minimallyinvasive techniques are crucial. In this context, nanoparticles havealready demonstrated their utility in medicine by applying imagingtechnology to the targeting and visibility of tumors, enabling earlycancer detection. Targeted drug distribution is another biomedi-cal use of nanoparticles. Intelligence nanocarriers might enhancetreatment efficiency by transporting anticancer medications to a pre-determined location where their release occurs without damaginghealthy tissue.1,2 Nanomedicine uses nanoparticles for diagnosing,detecting, monitoring, treating, and curing illnesses beginning at themolecular level using designed nanocarriers, which is the word forusing gy for medical needs.3 Using products and substances between1 and 1000 nm in size characterizes nanoparticles as a completeresearch field.4To handle lipid problems, inflammation and angiogenesisinside atherosclerotic plaques, and the protection of thrombo-sis, among other ailments, nanoparticles may offer a secure andefficient foundation for regulated medication delivery for vari-ous active components.5 Nanocarriers are special because of theirsmall dimensions, high specific surface area ratios, and advanta-geous physicochemical characteristics. They may alter medications’pharmacodynamic and pharmacokinetic characteristics, improv-ing their treatment efficacy. Drug content on nanocarriers canimprove in vivo behavior, prolong the duration a molecule spendsin the bloodstream, and enable codrug-controlled release byenabling medications to accumulate, ideally near the tumor site.Nanomedicine substances can change how pharmaceuticals are dis-tributed throughout the body.6 At the heart of magnetic deliverymethods are magnetic nanoparticles (MNPs), designed to targetsite-specific malignancies while potentially providing a controlled-release pattern appropriate for treating diseases. MNPs can beemployed in nanomedicine as optional possibilities for medication-targeted treatment when employing an external load magnetic fieldbecause of their multi-functional dimension. MNPs could be createdinto drug delivery platforms with dimensions that are equivalentto the organism’s antibody Levor molecules for enhanced bioactiv-ity while integrating therapeutic agents that might be challengingto distribute to cancerous cells because of their adjustable physic-ochemical characteristics as well as the large ratio of surface tovolume standard for nanomaterials.7 To upgrade existing systemsfor in-vivo usage, MNPs must be involved. Since the polymer shellfunctions as a compatibilizer that communicates with its surround-ings, providing functional places that are catalytically or biologicallyeffective, and since MNPs have unique characteristics that allowmanipulation of the processes, combos of MNPs and polymers areappealing to investigators interested in creating stable compositeor colloidal processes. Figure 1 illustrates the many applicationsof MNPs, including biological separation, hyperthermia, catalysis,MRI, magnetic drug target delivery, nucleic acid and cell separation,COVID-19 detection, and biosensors.Nanoparticles have been discovered to help gather data at allphases of clinical procedures due to their application in several inno-vative tests to cure and diagnose procedures. The major advantagesof these nanomaterials are linked to their surface characteristicsbecause different proteins could attach to the surfaces. For exam-ple, nanoparticles are utilized as tumor tags and indicators in variousFIG. 1. Various biomedical uses of MNPs for therapy.APL Mater. 12, 010601 (2024); doi: 10.1063/5.0191034 12, 010601-2© Author(s) 2024 31 January 2024 17:27:13https://pubs.aip.org/aip/apmAPL Materials REVIEW pubs.aip.org/aip/apmbiomolecule identification procedures. When using nanoparticlesfor the delivery of drugs, the physical properties of the medicationare taken into consideration when choosing the nanoparticles. Usingbioactive natural chemicals with nanoelectronics is highly appealingand has grown significantly in recent years. When it comes to thedistribution of natural remedies for treating cancer and numerousother disorders, it offers several benefits. A wide range of uniqueproperties of natural products, including their ability to inducetumor-suppressing autophagy and their ability to act as antibiotics,have led to extensive research into their potential as therapies formany disorders.8Such procedures involve highly sensitive magnetic nanoparti-cles and feasible magnetic application devices to be fully clinicallyeffective. Nanoparticles flow along a magnetic field’s gradient, andfrequently, magnetic values are decreased to zero just a few mil-limeters away from a permanent magnet. This makes it difficult tocreate magnetic properties that sufficiently affect particle movementinside organisms. Higher force gradients may be achievable withnovel magnetic field deployment techniques, enabling the material’smovement far deeper inside the body.9 Moreover, as such infor-mation is necessary for any therapeutic application, systems thatcan successfully predict magnetized particle mobility in complicatedin vivo environments will be needed. Finally, the therapeutic effec-tiveness of these novel models and systems will depend on usingextremely sensitive, less harmful magnetic nanoparticles. When atumor is discovered, it has only a 50% chance of spreading locally.In these circumstances, it may be addressed using tried-and-truetechniques like radiotherapy, systematic chemo, or even tumor anti-bodies. For the remaining 50% of cases, potential surgery treatmentsare not accessible. A combination regimen of systematic radiationtherapy and chemotherapy treatment treats tumors with significantlocal dissemination.Nanoparticles (NPs) have drawn the interest of investiga-tors from various fields, including physics, chemistry, engineering,and biology, to synthesize, comprehend, and develop new poten-tial applications. MNPs have been used for scanning, diagnostics,biocatalysis, immobilization, regulated medication administration,prolonged and directed hyperthermia, and the treatment of can-cer.10 Magnetic nanocomposites, metal oxides, and pure metallicsare the typical classifications for magnetic NP. MNPs must possessan adequate degree of bioactivity and should not cause inflamma-tion or cytotoxic responses in the body to be used as a nanocarrierfor therapeutic purposes. Just iron nanoparticles, especially its twooxidations, including magnetite and maghemite, can satisfy theserestrictions given the diverse magnetic nanoparticles.11 Because ironis present in so many bodily organs, including the heart, spleen, andliver, and because it serves as the structural basis for important bio-logical molecules like hemoglobin, myoglobin, and ferritin, they arebiocompatible.12At pH 7, MNP ought to have high solubility in water. They mustalso demonstrate an elevated magnetization level to regulate theircirculatory transit using magnetism and immobilize them withinspecific sick tissues. MNPs may enter cells by endocytic meansand have several desirable characteristics, including a large surfacearea, a high specific surface area ratio, the flexibility of separatingusing outside magnetic fields, rapid mass flow, and the potentialto be functionalized for stimuli-responsive impacts.13 A significantestimation of the homogeneity level in NP dispersion is the polydis-persity index (PdI). Its value normally ranges from 0 to 1, with a risein PdI values indicating a larger size dispersion in the NP collection.Monodisperse NP samples are those with PdI values less than 0.1.Changes in the PDI can be utilized to detect aggregating or physicalinstabilities.14 The efficient treatment uses the mono-dispersibilityof NP since it allows for precise estimation of their pharmacokineticbehavior after delivery.15With an emphasis on the methods of focused and imaging-assisted drug administration, this review gives an overview of cur-rent developments in the creation and use of MNPs for the deliveryof drugs. MNP kinds, characteristics, drug delivery systems, activetargeting strategies, and therapeutic application are only a fewsubjects covered in this domain.The anticipated contributions of this review paper are asfollows:● This paper presents a comprehensive analysis of the mostrecent advancements in the area of magnetic nanoparti-cles and gives a wide-ranging summary of their uses innanomedicine.● The incorporation of magnetic nanoparticles into biomedi-cal applications, particularly in the administration of med-ications, is a major topic of discussion in this study.With the increasing interest in using nanotechnology toimprove medication distribution methods and healthcare,this concern is essential.● The work addresses novel uses for magnetic nanoparticleswithin nanomedicine, including hyperthermia treatmentand the specific delivery of drugs.● In the framework of innovative therapeutic alternatives,this study highlights the clinical application of magneticnanoparticles.● It offers a basis for knowing the present state of the practiceand acts as a basis for more study and advancement in thisexciting field of nanomedicine.The following portions of this paper are arranged as follows:In Sec. II, they give a summary of the many varieties of magneticnanoparticles. The therapeutic properties of MNP are discussed inSec. III. A detailed presentation of nanomedicine-based cancer ther-apy is provided in Sec. IV. An overview of inorganic nanomedicine-based cancer therapy is provided in Sec. V. In Sec. VI, a magneticparticle characteristic is reviewed. Section VII provides an explana-tion of the magnetic nanoparticles’ properties. A detailed presenta-tion of nanoparticles in medicine is provided in Sec. VIII. Section IXpresents the use of nanotechnology. Food and Drug Administration-approved nanomedicines are included in Sec. X. The conclusion isfinally provided in Sec. XI.II. COMPREHENSIVE EXPLORATION OF MAGNETICNANOPARTICLES IN NANOMEDICINEThe review deals with many different things related to usingtiny particles in medicine, especially magnetic ones. This exploresthe different kinds of tiny particles that have magnetism and theirspecial qualities, like being able to help with healing. The articleAPL Mater. 12, 010601 (2024); doi: 10.1063/5.0191034 12, 010601-3© Author(s) 2024 31 January 2024 17:27:13https://pubs.aip.org/aip/apmAPL Materials REVIEW pubs.aip.org/aip/apmtalks more about how nanomedicine can be used to treat cancer,and it shows how it has the potential to be very effective. In addi-tion, it shows how small particles not made from living things canbe used to treat cancer and gives a detailed look at the characteristicsof magnetic nanoparticles. This text is about how nanotechnology isused in different ways in medicine. It also talks about the rules andregulations that govern these medical technologies.The article deals with using tiny particles called nanoparticlesin medicine, specifically focusing on magnetic nanoparticles. Thistext talks about different kinds of small magnetic particles and whatmakes each of them special, especially their ability to help with heal-ing. The article discusses how nanomedicine can be used in cancertreatment and highlights the exciting possibilities it offers. More-over, it talks about using tiny particles in cancer treatment andthoroughly examines the traits of magnetic particles. This text talksabout how nanotechnology is used in medicine. It also mentions thatthere are some medical treatments that have been approved by theFDA. It explains how these treatments are regulated.III. NANOPARTICLE IN THE MEDICAL FIELDA. MaterialFerrites with the basic chemical formula M (Fe2O4), where Mmay represent a divalent action like nickel, cobalt, magnesium, orzinc, magnetite (Fe3O4), and magnetite are the three most populartypes of magnetic nanoparticles (Fe2O3). Nickel, cobalt, and iron area few examples of novel nuclei.16B. Types of nanoparticles in medicineThe preparation techniques used, such as the emulsified poly-merization process, mini-emulsion polymerization, microemulsionpolymerizations, and emulsion-solvent evaporative cooling proce-dures, all have a significant impact on the morphological featuresof polymeric NPs (such as spheroid, bolts, and diskettes), size andshape distribution, and physiochemical properties. Nanospheres, ormicrocapsules, are two different types of polymeric nanoparticles.The active chemicals can be deposited on the material surface orretained in the NP matrices by either physical encapsulation orchemical coupling. Nanostructures are large colloidal NPs (whoseshape does not always remain round). The application of chitosanin biosensing is a particularly intriguing field of study. Chitosanwas able to be conjugated into a variety of nanomaterials becauseit contains amino and hydroxyl sites. This sparked research andthe creation of chitosan-nanocomposite-based biosensing, whichmonitored glucose, DNA, and proteins. These sensors also use nan-otechnology and several other polymers. Excellent research observedencouraging outcomes when everolimus was delivered to lungs mes-enchymal cells specifically and specifically utilizing chitosan-basedparticles covered with hyaluronic acid. Chitosan and gelatin wereused to create a nanocomposite scaffold that contained bovine serumalbumin and basic fibroblast growth factor (bFGF)-loaded chitosannanoparticles (BSA). The findings showed continuous productionof a protein, together with a notable increase in fibroblast cellu-lar proliferation. Moreover, Cai et al.17 created auto-fluorescentgelatin nanomaterials that were MMP-responsive probes for imag-ing cancerous cells. The work established a straightforward synthesismethod, demonstrated the bioactivity of polymers, and gave a clevermethod to watch the behavior of cancer cells. Cai et al.17 revealedintriguing outcomes for oral subcutaneous insulin delivery usingchitosan- and sodium tripolyphosphate-based nanoparticles loadedwith adrenaline.C. Core shell structureMetallic cores covered with biomaterials, which are increas-ingly used for simpler processing and superior management, areFIG. 2. Types of core shell.APL Mater. 12, 010601 (2024); doi: 10.1063/5.0191034 12, 010601-4© Author(s) 2024 31 January 2024 17:27:13https://pubs.aip.org/aip/apmAPL Materials REVIEW pubs.aip.org/aip/apmmentioned in Fig. 2. Magnetite nanoparticles that have structuralproperties and magnetic iron oxide that is either in the form ofmagnetite (Fe3O4) or magnetite (Fe2O3). Substances like silica, dex-tran, polyvinyl alcohol (PVA), or gold and other metals that maybe packed together are used to create the structure model; suchparticles are created by ionic and non-ionic surfactants or by encap-sulating inside of peptides or carbon cages such as ferric. Theanalytical numerical methods investigated in the literature18–30 areused to investigate the structure model of these particles. Carboxylic,amino group adsorption, biotin, streptavidin, or antibodies thenfunctionalize these particles.It takes the form of biocompatible porosity resins that containmagnetic nanoparticles. This approach’s benefits include generat-ing particles with spherical shapes and a comparatively small sizevariation.IV. MAGNETIC NANOPARTICLE TYPESIn addition to having unique relevance in physical theory, mag-netic nanoparticles (MNPs) are a novel form of nano-magneticsubstance with several uses in the biomedical industry. MNPs aretypically magnetized composite materials made of metals and theiroxidation, such as iron, nickel, cobalt, etc. Typically, X-ray distri-bution (XRD), scanning electron microscopy (SEM), transmissionelectron microscopy (TEM), and other techniques are used to char-acterize the structural features of MNPs.31 MNPs are typically super-paramagnetic and mostly composed of superparamagnetic nanopar-ticles of iron oxide when their dimension is smaller than 50 nm(SPIONs).32 Such MNPs are currently mostly utilized to research thefunctioning of MNPs in vivo since they display non-permanent mag-netization or the ability to become magnetized in the presence of anexternal magnetic force. The tracking techniques apply to magne-tized nanoparticles. They may transport a range of tiny molecules,proteins, RNA, etc., because of their enormous specific surfaceareas. Nanometal particles’ magnet characteristics make it simplerto enhance, segregate, transport, and identify them in differentdirections. Under high-frequency magnetism, MNPs have a magne-tocaloric action that can inadvertently kill tumor cells.33 Nowadays,MNPs are often employed in medicine for therapy, medicationadministration, supplemental evaluation, and identification.A. Magnetic nanoparticles with a silica coatingMagnetic nanoparticles coated with nanosilica are silica-coatedmagnetic particles (nSiO2). Because of their outstanding thermalproperties, magnetic characteristics, chemical stability, and non-toxicity, compounds have received greater attention.34 Interactionwith organosilane molecules is a typical technique for modifyingsilica-based substances to provide the possibility for an organic syn-thesis process. Recently, it has become a growing sector, and mostapplications use SPIONs.34 Nanomaterials with spherical shapesare called nSiO2 microspheres. They have received much studyand use in medication transporters and controlled drug release inrecent days. By injection, percutaneous infiltration, or inhalation,nSiO2 microspheres can enter living things. Among these, inhal-ing through the lungs allows the nSiO2 microparticle drug-carryingdevice to immediately pass the “blood–lung barrier” and enter thebloodstream, attaining systemic administration.35 A novel class ofmagnetized silica nanoparticles may be created by wrapping ironoxide nanoparticles in nSiO2 microparticles. The silicon surfaces canthen be functionalized using –COOH, –NH2, or –OH to continue torespond.B. Magnetic nanomaterials with a lipid coatingMagnetic liposomes are colloid structures created wheneverphospholipid bilayers encircle magnetic nanoparticles. A nano-scaleiron oxide-phospholipid combination was the subject of the ini-tial theory and description of magnetized liposomes. It is commonpractice to manufacture lipid-coated magnetic particles utilizingmicroemulsion and various emulsified processes.36 Emulsions arebioreactors for creating iron oxide bodies with lipid coatings onmagnetic particles. The base of a traditional magnetic liposome is aniron oxide substance with a dimension of around 14 nm, and the out-side is covered with a phospholipid bilayer. This particuliposome’sinterior cavity is filled with i particles. This magnetized liposomeexhibits elevated iron oxide body concentrations to ensure maxi-mum cytotoxicity. This arrangement can enhance the absorption ofiron by cells at low temperatures. It is among the most important cellmagnetic indicators because of its excellent biocompatibility, tar-geted selectivity, and other benefits, notably magnetism liposomesformed on SPIONs as a T2 contrast material broadly employedin nuclear magnetic resonance.37 The phospholipid bilayer servesas the skeleton of the vesicle-type magnetic nanoparticle, a uniquestructure of the MNP scattered throughout. Vesicle-type nanopar-ticles are a subclass of liposomal particles that have recently drawnattention from researchers because of their superior drug-holdingability. By utilizing dimensions excluding chromatography to incor-porate superparamagnetic maghemite particles in lipid unilamellarvesicles, it is easy to create vesicle-type magnetic particles.38 Vesicu-lar magnetized liposomes can be categorized into one of three groupsbased on where the magnetic nanoparticles are located within theliposomes: Liposomes containing hydrophobic MNPs in the inter-nal aqueous cores, hydrophobic nanocomposite liposomes that areenclosed in a phospholipid bilayer, and MNPs that are implanted onthe exterior of the phospholipid membrane all include hydrophobicMNPs in the aqueous solution.39 The MNPs comprised of vesicle-type magnetized liposomes are typically 1–10 nm in size. Therefore,there will not be any issues with blood capillary obstruction or aggre-gation. It may be easily expelled from the body because of thisproperty. It is utilized in biomedicine as a medication transporter,hyperthermia intermediate, and magnetic resonance contrastingagent due to its excellent biocompatibility and low toxicology.C. Magnetized nanoparticles with a polymer coatingPolymer nanocomposites were created at the point wherethe areas of polymeric material and inorganic nanoparticles met.Owing to MNPs’ high energy content and substantial surface area,which make it challenging to distribute them evenly in polymers,their study and use are severely constrained. Therefore, improvingthese phenomena through polymer modification is a good option.Presently, two processes—chemical covalent bond alteration andself-assembly—are used to create magnetized polymeric drug car-riers.40 As the study has progressed, several scientists have alteredthe active groups on the surfaces of MNP transports and packedbiomolecules with functionalities that respond to stimuli on theAPL Mater. 12, 010601 (2024); doi: 10.1063/5.0191034 12, 010601-5© Author(s) 2024 31 January 2024 17:27:13https://pubs.aip.org/aip/apmAPL Materials REVIEW pubs.aip.org/aip/apmcarriers dependent on MNPs. This has been built upon to cre-ate a responding magnetized polymeric drug-carrying platformconsisting of several smart nano-drug-controlled-release devices.41D. Superparamagnetic iron oxidenanoparticles (SPIONs)The most significant component of magnetic nanoparticles isoxidized iron, primarily Fe3O4 and Fe2O3. Significant paramagneticenergy may be produced because of the sequences of delocalizedelectrons outside of the nucleus of the iron, which create a netmagnetism vector. Iron oxide nanoparticles will display superpara-magnetic behavior whenever their dimension is below a certaincutoff at the legal limit. Aggressive pressure and magnetization willboth decrease concurrently. When a nanoparticle is exposed to amagnetic field, it can become magnetized very fast, and when themagnetic field is eliminated, the magnetization rapidly dissipates.A nanoparticle called SPION, which has a crystalline core made ofFe3O4 or –Fe2O3, with a dimension of 10–100 nm, can create highmagnetization in an exterior magnetic field but loses that magnetiza-tion when the exterior magnetic field is removed.42 Microemulsions,laser pyrolysis, and sol–gel procedures are a few techniques forcreating nanoscale metal cores. Nonetheless, co-precipitation andthermal degradation are the two primary processes for their for-mation. Due to its superparamagnetic characteristics, SPION hasseen extensive usage in the biomedical realm. Several SPION for-mulations are being tested in medical studies, and it is becomingincreasingly clear that they are effective.43 SPION is biocompatiblein a positive way. For those with impaired liver and renal func-tioning, this could bind to hemoglobin through the body’s naturalphysiologic and metabolic processes to prevent buildup. SPIONcan also increase T2WI and decrease T2WI signal intensity. It hassignificant application value in detecting, identifying, and treatingtumors.44V. HEALING CHARACTERISTICSDespite significant advances over the 21st century, the averagelifespan is still short in several places, and malignancy is a fre-quent and growing primary cause of severe medical problems andincreased mortality. In the European Union exclusively, it is pro-jected that 1.3 × 106 people will die from cancer in 2022.45 MNPcompositions induce a range of tumors and malignancies. The shiftof MNPs from basic research to practical alternatives in oncologictherapy, theranostic usage, and drug delivery methods represented amilestone. MNPs immobilized with antibodies can produce potentsensing platforms. Numerous biological uses, such as the therapy ofcancer and malignant cells, have been identified.46A. Delivery of drugsA wide range of MNPs and targeted drug loadings are nowcovered by systems for drug delivery, incorporating intraocular dis-tribution using intelligent microrobot technologies or the distribu-tion of erythropoietin-hybridized MNPs for the therapy of nervoussystem injuries.47 The toxicity of magnetized nanosystems for thedistribution of conventional platinum-based anticancer drugs wasstudied in vitro.48 It has been demonstrated that form has a sig-nificant role in cytotoxicity, with spherical-shaped NPs being muchless harmful than analogous cylindrical or elliptical shapes, particu-larly when the quantity of reactive oxygen species (ROS) is elevated.TABLE I. The summary of current drug distribution criteria for drug-delivery treatments.ReferencesNanoparticlestypesCreation of MNPsand coatingsMedication ormolecular typeParticularillness/application52 NiFe2O4 Trichloroacetic acid(BTC) serves as theorganic binder for MOFin the core-shell methodAdsorption ofcurcumin in amesoporous hostingDelivery of drugs53 MMS using Fe3O4 Co-precipitation and theW1/O/W2 technique forevaporating solvents fromternary emulsions5-fluorouracil 5-fluorouracil54 ZnFe2O4 using NHSs Solvothermal technique Doxorubicin Therapy for cancer55 Fe3O4 and SPIONs Co-precipitation;stabilization of dextran(DEX)Camptothecin (CPT)effect on AT3B-1cancer cellsProstate cancer56 Fe3O4 PEG, hyaluronic acid,dextran, and conjugatedhuman plasma albuminErlotinib, gallic acid,doxorubicin,cetuximab, quercetin,and acteinLungs cancer57 Using Fe3O4 NPs, themagnetic hydrogelThe technique ofco-precipitation;production of hydrogelDoxorubicin (DOX) Hyperthermia and breast cancerAPL Mater. 12, 010601 (2024); doi: 10.1063/5.0191034 12, 010601-6© Author(s) 2024 31 January 2024 17:27:13https://pubs.aip.org/aip/apmAPL Materials REVIEW pubs.aip.org/aip/apmEffective drug distribution using MNP-coated nanomaterials neces-sitates a complete understanding of the drug molecule’s proteicactivity.49 Pharmacokinetic behavior is of the highest significanceas it can result in improved medication delivery and, as a result,more effective illness therapy and control. For efficient performanceat the intended place, medicines, genes, and other physiologicallysignificant compounds can be coupled with NPs. There have beenseveral publications on uses for drug delivery that handle a range ofdifficult-to-target cancers or diseases.50 Table I depicts the currentdrug distribution criteria for drug-delivery treatments.B. Cellular medication absorptionPaclitaxel (PTX), also known by its brand name Taxol, is achemotherapeutic drug used to treat a variety of cancers. The porousstructure of MNPs that contains mesopores (Dp = 2–50 nm) signif-icantly improves their ability to ingest various physiologically activechemicals. A thin line separates cellular uptake and aggregation,and MNPs must only assemble at the targeted area if malignancyor tumor cells are present.51 The absorption of NPs by cancerouscells has been seen using other in situ/operando characterizationtechniques. Moreover, Raman spectroscopy was used for this goalwhenever tumor cells were exposed to Co-NPs. When utilizingbiomimetic MNPs, enhancements in cellular uptake were seen, con-firming once more that the secret to getting beyond biologicalobstacles is to leverage other bio-inspired processes.52C. HyperthermiaRecent studies have examined magnetic nanoparticles studiedfor biological and thermal applications.58 Uses for hyperthermiaare of special interest because they could open up new avenuesfor diagnosing and treating illnesses and identifying, administer-ing, and preventing cancer.59 Several difficulties involving using aferrofluid medium and crucial heat transfer problems have beenresearched. For applications involving therapeutic hyperthermia orthe modeling of magnetic gel behavior under magnetic direction,discrete Fourier transform (DFT) modeling utilizing the MonteCarlo approach is also accessible.60 The influence of Ti ions onMNPs’ Néel relaxing, the release of drug modeling using the zerothordering, first order, Korsmeyer–Peppas or Higuchi model kineticparameters, the magnetism decreases necessary for sustained hyper-thermia, and other processes have all been the subject of detailedmechanistic investigations. Important characteristics of MNPs thatcorrelate with how well they function in hyperthermia studies havebeen uncovered through theoretical models. A few of these stud-ies have identified the ideal aspect ratio for the greatest warmingimpact. The temperature reduction process was revealed to be highlydependent on the heating rate of a core–shell magnetic NP structure,closing the loop in the heat treatment.61D. HypoxiaHypoxia, when the body’s tissues have inadequate oxygen sup-ply, is a turning moment in the fight against cancer resistant toconventional or focused therapy. The hemoglobin molecules oxyhe-moglobin and deoxyhemoglobin are created when oxygen attachesto hemoglobin. These two aspects undergo concentration changesthat may be seen using the functioning MRI (fMRI) method:BOLD MRI.62 Whenever H–MnFe(OH)x hydroxide nanocapsuleswere created with significant loading, for instance, employing achemotherapy medication, doxorubicin (DOX), within both in vitroand in vivo actual evidence of antitumor synergies, degradable Fe-based nanohybrids were employed for hypoxia-modulated tumortherapy.63E. Drug targeting utilizing magnetsAt the forefront of biomedicine and diagnostics is findingan efficient therapeutic strategy for targeting cancer and tumors.64This is an outcome of conventional chemotherapy becoming non-specific, allowing the potent anticancer medications to injure normaltissue. MNPs react to an outside magnetic field, providing a wayto direct the distribution of magnetized nanocarriers carrying lethaldrugs to the intended organ or tissue. This procedure is complicatedby several factors, such as the speed of blood circulation, the waydrugs are immobilized on MNP carriers, the poor diffusing controlsafter intravenous infusion, the shape of the afflicted organs, and theirdepths. Furthermore, accurate diagnosis is crucial for the survival ofafflicted individuals to improve their chances of survival, particu-larly when the therapeutic formulations must target certain organsor tissues.65Many organizations investigated the flow behavior of multi-disciplinary team (MDT) as well as their capacity to enter varioustissues, including ocular tissue. The regulation of NP aggregat-ing is crucial and is handled by numerically solving the vorticitystream-function formulations when the targeting illness is locatedat the arterial segment.66 Numerous research teams looked into thepossibility of presenting multiple core MNPs of less than 50 nmvia tissue of the cornea utilizing a magnetic field gradient of20 T m−1 or the prospective disposal of MNP-tagged cytokines dur-ing cardiopulmonary bypass utilizing simulation studies dependingon Navier–Stokes calculations.67 The depth element of the tumorappears to be common since many study groups concluded thatthe greatest outcomes in MDT can only be reached when dam-aged tissues are near the body surface. In addition, understandingand improving the drug-delivery nanovehicles requires a thoroughunderstanding of MNP activity in the coronary circulation system.68F. Delivery of drugs on demandHybrid compositions with nanotechnology can discharge theloading molecules when needed, but they can also leak divalentcations from ferrous composites.69 Theoretically, the magnetic coremust maintain its integrity during its journey through the biologicalprocess; however, the leaching test described is crucial proof of itsintegrity.G. ApoptosisAnother significant accomplishment of using SPIONs is theprocedure of programmable cell death (apoptosis); HT-29 cells havedemonstrated apoptosis by SPIONs.70VI. CLINICAL CANCER TREATMENTUSING NANOMEDICINEDrug conjugates, viral vectors, polymer-based nanocarriers,lipid-based nanocarriers, and inorganic nanoparticles are only a fewAPL Mater. 12, 010601 (2024); doi: 10.1063/5.0191034 12, 010601-7© Author(s) 2024 31 January 2024 17:27:13https://pubs.aip.org/aip/apmAPL Materials REVIEW pubs.aip.org/aip/apmexamples of the several kinds of nanomedicine substances that havebeen employed in therapeutic cancer treatment.A. Cancer treatment with viral nanoparticlesCombining tumor-homing virus with medicinal proteinexpression is a sophisticated method of creating nanoparticles forcancer treatment. Myxoma and vaccinia strains of the pox virustend to proliferate in tumor cells. Effective pox virus replication alsobenefits from unique traits of cancerous cells, such as blockage ofapoptotic pathways, dysregulation of cell reproduction, and immuneevasion.B. Cancer treatment with organic nanocarriersSeveral synthetic or natural substances intended for focused ornon-targeted medication delivery compensate for organic nanocar-riers. Pharmaceutical conjugates, lipid transporters, protein carriers,glycan carriers, and synthetic polymer carriers are the broad cate-gories into which they may be separated. Although drug conjugateshave successfully entered the clinical setting, there have been onlyhesitant attempts to do the same with nanocarriers consisting oflipids, proteins, or polymers.VII. CONJUGATED DRUGSPharmaceutical conjugates have become the most effectivenanomedicine therapies in the treatment of cancer patients. Thesmall scale in the smaller nanometric range and subsequent conju-gation to active pharmacological substances. The targeting peptide,antibody, and polymer are covalently attached to the active ingre-dients. The conjugation, which is often mono- or oligomeric, isdesigned to increase the drug’s focused distribution while having lit-tle to no effect on the drug’s solubility and stability. The medicine isoften enclosed by nanocarriers made of lipids, enzymes, and glycans,eliminating the requirement to attach the medication to the carriers.A. Nanocarriers with a lipid basisSeveral lipid-based nanocarrier structures, liposomes, andmicelles are among the most often studied. In comparison to ADCs,which generally contain 1–6 active ingredients per monoclonal anti-body, lipid nanocarriers have a maximum capacity that is threeto four times greater. Non-PEGylated liposomal doxorubicin, vin-cristine sulfate liposomes, non-PEGylated liposomal daunorubicin,liposomal mifamurtide, and non-PEGylated liposomal cytarabineare five further lipid nanocarriers that have been given the green lightfor therapeutic application.B. Synthetic polymer-based nanocarriersBIND-014 is the initial target of polymer nanoparticles in med-ical tests. It comprises PLGA-PEG nanoparticles targeting prostate-specific membrane antigen coated with docetaxel (PSMA). BIND-014 contains up to ten times more docetaxel administered to tumorsthan free docetaxel in several model organisms.VIII. Cancer treatment with inorganic nanoparticlesApplications of inorganic nanoparticles range from drugadministration to radiation enhancement to tumor imaging. Thenanoparticles of iron oxide are mostly employed for diagnostics rea-sons, while they have also been evaluated in human clinical trialsfor tumor imaging using magnetic resonance. An aqueous colloidaldistribution of nanoparticles of iron oxide is called NanoTherm®.An alternate magnetic field application is used to accomplishthermos-ablation after injecting the tumor.IX. MAGNETIC PARTICLE CHARACTERISTICSeveral initiatives have been undertaken in recent times tomanufacture and synthesize magnetic nanoparticles for use in var-ious industries, including biotechnology, therapeutic agents, andcomputers. Generally speaking, these NPs’ implementation out-comes are predicated on their practical structure and synthesis.Several different MNP kinds are currently being created. Several dif-ferent MNP kinds have so far been created. Metal oxides (Fe2O3,Fe3O4), ferrites (MFe2O4, M = Cu, Ni, Mn, Mg, etc.), pure metalnanoparticles (Fe, Ni, Co), and base metals constitute the mostprevalent of these (FePt, CoPt). The manufacture of these nanopar-ticles should take into account several important factors, includingtheir intrinsic magnetic characteristics, structure, size, protectivecoatings, charge density, persistence in aquatic media, and non-toxicity. The dimensions, structure, protective coatings, and chem-ical stability of magnetic nanoparticles could be best regulated byselecting an appropriate synthesis technique. Iron oxides typicallyhave a significant impact on the selection of a magnetization. Com-pared to other magnetic nanoparticles, these compounds have goodmagnetic characteristics on one side and strong resilience over dete-rioration. The following points present the main characteristics ofmagnetic nanoparticles:The crystalline phase of MNPs is required, and there can beonly one area per particle.● Nanoparticles should have a consistent size and shapeand a restricted diameter. A sample should contain onlyidentically shaped nanoparticles throughout.● Spherical nanomaterials are what they typically employ.Naturally, they also use additional advanced structures likenanorods and nanotubes.● Stability and biocompatibility: These are two requirementsfor biomedical field systems that could be addressed by corearchitectures, which have a metallic or metal oxide base anda covering of polymeric or inorganic compounds on top.It has been discovered to bond to biomolecules or impartbiocompatibility to nanomaterials.● Tiny size and hemodynamic length: a size of less than 50 nmis yet another character in this subject as a result of the factthat it promotes diffusion and prevents particulates frombeing eliminated by the body’s reticuloendothelial system(RES).X. PROPERTIES OF MAGNETIC NANOPARTICLESMNPs must be robust, nontoxic, and biodegradable to beused in vivo. These characteristics could be controlled by alteringthe nanoparticles’ diameter and the coating’s characteristics. Fe,nickel, and cobalt are metallic materials that have been demon-strated to be harmful due to corrosion and acid erosion. These fac-tors make shielding magnetic particles necessary to safeguard themAPL Mater. 12, 010601 (2024); doi: 10.1063/5.0191034 12, 010601-8© Author(s) 2024 31 January 2024 17:27:13https://pubs.aip.org/aip/apmAPL Materials REVIEW pubs.aip.org/aip/apmagainst deterioration. Magnetic nanoparticles must penetrate pastthe reticuloendothelial system (RES) for biomedical applications.The opsonization process starts when nanoparticles are injected intothe bloodstream. In this procedure, plasma-coated nanoparticles arelater destroyed by phagocytic cells and prevented from reaching tar-get cells. To prevent this from happening, nanoparticles are coatedwith either an organic layer made of surfactants and polysaccharidesor an inorganic layer called silicon and charcoal. The MNPs’ cyclingtime and colloidal stability may be increased by this extra layer.A. Size● The ideal choice for in vivo models is tiny nanoparticlesbetween 10 and 50 nm in size since they have severaladvantages.● By lowering the magnetic contact of nanoparticles, colloidalstability can be increased, and aggregating can be avoided.The size of NPs must possess superparamagnetic character-istics to achieve this. As a result, size reduction is required toattain superparamagnetic characteristics.● The dipole–dipole interaction is related to the particle sizeof the sixth power. Because of this, decreasing size resultsin smaller dipolar interactions and a lessening of particleagglomeration.● The precipitation could be avoided by small NPs.● At a fixed quantity, small nanoparticles have a greaterarea on the surface. This could increase the covering andtargeting processes’ effectiveness.● At a pH = 7, small NPs may be stable in water.B. Control capabilityThe feedback control of magnetic nanoparticles is guaranteedby the gradients of the external magnetic field coupled with theintrinsic permeability of the magnetic fields within human cells. Thisfunction and remote control are used for the transfer and depo-sition of MNPs, the targeted transfer of anticancer medications tothe tumor location, the labeling of specific biological components,and other related activities. The power could be transmitted fromthe stimulated fields to the nanoparticle via these atoms, whichcould also react in resonance to field-time-dependent alterations.Chemotherapy and radiation therapy both use it as a tonic.71XI. APPLICATION OF NANOTECHNOLOGYA. Biomedical applicationIn essence, every medicine molecule is a creation of natural orartificial nanoengineering. As an illustration, the typical aspirin, themost popular and efficient medication, is only 0.6 nm in size. Ther-apy immunotherapies, measuring around 30 nm in width, are onthe large side. Hemoglobin is one of many polypeptide chains witha diameter of 5 nm, and natural molecules of a similar size may alsobe employed therapeutically. The mammalian cell’s double-strandedDNA is packed tightly into its 2- to 5-Am-diameter nucleus, witha width of ∼2.5 nm and a length of about 2 m. The next genera-tion of cancer therapies created by nanotechnology applications willcompletely depend on monoclonal antibodies. They serve as imag-ing tools, drug targets, drug transporters, and even drug molecules.At least nine FDA-approved antigens are now being tested in clinicalstudies to be employed for cancer treatment. The ability to logicallycreate and synthesize efficient small-molecule inhibitors of proteinactivity constitutes one of the greatest discoveries in therapeuticdiscovery. The use of applications of nanotechnology, which havebeen around for a while, would eventually result in the creationof various medications. For instance, targeted proteins and theirligands or intermediates are employed as a blueprint for the logi-cal design of novel medications using nuclear magnetic resonanceand x-ray crystalline structure. Using cancer therapy or vaccinationsis an intriguing strategy for eliminating tumors. Small tumors areTABLE II. Evolution of nanodrug delivery system.Year Nano-drug1989Polymeric particles● Lupron● Endometriosis1990 PEGylation● Adagen1995 Liposomes● Doxil1995 Lipid disk● Amphotec1995 Nano/microemulsion● Neoral1996 Iron oxide● Feridex2002 Polymer micelles● Estrasorb2003 Nanocrystal● Emend2005 Albumin NPs● Abraxane2010 Virus-like particle●Human papillomavirus vaccine2013 Hydrogels● TraceIT2015 Oncolytic viruses● Imlygic2018 Lipid and nucleic acid● Onpattro2020 Lipid and nucleic acid● COVID-19 vaccine2021 Nanocrystals● CabenuvaAPL Mater. 12, 010601 (2024); doi: 10.1063/5.0191034 12, 010601-9© Author(s) 2024 31 January 2024 17:27:13https://pubs.aip.org/aip/apmAPL Materials REVIEW pubs.aip.org/aip/apmbelieved to be eliminated by the body through an effective immunereaction, but aggressive cancers could eventually evolve defense sys-tems that prevent the host from detecting their presence. The systemought to be capable of eliminating the tumor if techniques to stim-ulate the immune function against such tumors could be developed,and this kind of chemotherapy may be effective against every kindof cancer. To increase the autoimmune reaction against the illness,the tumor antigen is not particularly immunogenic. The antigenshave been coupled to solid-core nanobeads in a novel vaccinationformulation.19B. Industrial applicationsMagnetic iron oxides are frequently employed as synthetic pig-ments in porcelain, paints, and ceramics. Magnetics might be quiteuseful in many facets of life and in several industrial sectors. Bothfrom the perspective of the fundamental study of materials sci-ence and their applications, such materials are fascinating.20 Manysignificant processes, including the production of NH3, the high-temperature water–gas shift reaction, and the desulfurization of nat-ural gas, have used hematite and magnetite as catalysts. Additionalreactions include the Fischer–Tropsch synthesis of hydrocarbons,the large-scale production of butadiene, the oxidation of alcohols,and the dehydrogenation of ethylbenzene to styrene.21C. Environmental applicationsThe enormous adaptability of nanoscale iron particles for insitu applications is a similarly significant characteristic. To furtherincrease the speed and effectiveness of iron nanoparticle reme-diation, improved iron nanoparticles such as catalyzed and sup-porting nanoparticles have been created.22 Iron nanoparticles arebeing acknowledged as a flexible technique for the remediation ofmany types of pollutants in groundwater, soil, and air on boththe experimental and field scales, despite certain remaining unre-solved issues related to their utilization.23 Several MNPs have beenresearched recently for the elimination of organic and inorganiccontaminants.XII. FDA-APPROVED NANOMEDICINEThe international demand for nanoparticle drugs is predictedto surpass US$200 billion by 2024 at a CAGR of 10%, accordingto the most recent study. For the next seven years, the nanocarri-ers industry is projected to rise at a compound annual growth rate of21.9%, according to a preliminary study of the economy. The U.S.is home to the biggest global market for medicine delivery usingnanostructures. The market is projected to be worth $12.8 billionby 2020. With a predicted market size of US$38.8 billion and aTABLE III. Nanomedicine and its carrier.Drug Nanocarrier Indicator Benefits YearDoxorubicinLiposomesOvarian ● Boost delivery to particular locations(tumor)● 1995; 2005● Reduction of systemic toxicity ● 2008Amphotericin B Fungal infection ● Reduction of toxicities ● 1995Daunorubicin Kaposi sarcoma ● Boost delivery to particular locations(tumor) ● 1996● Reduction of systemic toxicityCytarabine Lymphomatous meningitis ● Boost delivery to particular locations(tumor) ● 1997● Reduction of systemic toxicityAmphotericin BProtozoal pathogens or fungus ● Diminished nephrotoxic ● 1997Stress stimulator for the lungs ● Toxicity reduction● 1999● Enhanced administration for a lowervolumeVerteporfinDecreased vision ● Site-specific distribution is enhanced(lesion vessels) ● 2000Ocular histoplasmosis● Responsive to the light releaseMyopiaMorphine sulfate Pain loss ● Prolonged-release ● 2004Vincristine Acute lymphoblastic leukemia ● Boost delivery to particular locations(tumor) ● 2012● Reduce toxicityIrinotecan Pancreatic cancer ● Boost delivery to particular locations(tumor) ● 2015● Reduce toxicityPegademase bovine PEGylated adenosine Immunodeficiency disorder● Lengthen the body’s time spent inthe circulatory and reduce immunogenicity ● 1990Deaminase enzymeSevelamer HCL Poly Chronic renal disease ● Boost delivery to particular locations(tumor)● 2000APL Mater. 12, 010601 (2024); doi: 10.1063/5.0191034 12, 010601-10© Author(s) 2024 31 January 2024 17:27:13https://pubs.aip.org/aip/apmAPL Materials REVIEW pubs.aip.org/aip/apmCAGR of 24.5% from 2020 to 2027, China, the second-largest world-wide economy, is expected to have a marketplace of US$38.8 billion.Unquestionably highlighting the market’s capabilities and potential,the projected enormous growth of the NP market and particularlytargeted drug delivery raises the need for novel therapeutics to enterthe clinical stage to meet the rising demand for efficient treatmentoptions for the growing patient population.24–29Table II lists FDA-approved, classified nano-pharmaceuticalcompositions over time (polymeric nano-medicines, micelles, lipo-somes, antibody-drug conjugates, protein nanoparticles, inorganicnanoparticles, and nanocrystals). Table III presents an official ver-sion of FDA-approved nanomedicines organized by the kind ofnanomaterials used in them. This table was taken and altered fromthe publication by Yaylaci et al.30Table III shows the nanomedicine and its carrier with itsnanocarrier, benefits, and year. Figure 3 shows the number of drugspublished in different years.FIG. 3. FDA-approved nanomedicine.FIG. 4. Percentage of nanocarrier.Same as that, Fig. 4 presents the pie chart of mostly usednanocarriers. The figure shows that liposomes are the most widelyused, poly is used in at least one place, and adenosine stays inbetween at the mid-level.72–84XIII. CONCLUSIONAmong the scientific fields with the most rapid growth isnanomedicine, which is also one of the most potential cancer therapyoptions at present. Several nanomedicine frameworks have been cre-ated, and numerous of them are employed in the treatment of cancerpatients. MNP systems come in many forms and are now undergo-ing rapid development. The MNPs may be customized for illnessdiagnosis and therapy, including for both early-stage and late-stagecancers. The major objectives are obtaining improved biocompati-bility, precision-targeting, and a higher accumulation of target cellsfor appropriate biological reactions. Healthcare professionals canchoose from a variety of therapy approaches using multi-functionalMNPs. Due to their particular uses in fields including medical,sensors, the presence of body and environmental clean-up, mag-netic nanoparticles have various unique features. In addition todelivering genes, magnetic nanoparticles in the form of liposomesand polysomics are utilized to transport drugs. As a result, theuse of these nanoparticles in biological applications is widespread.Similarly, it is frequently employed in molecular sensors for the visu-alization and detection of several bacteria, fungi, and viral illnesses.When utilized in nanomedicine, magnetic nanoparticles have anumber of exciting new properties that make them useful instru-ments for a range of uses. Drug delivery, hyperthermia therapy, MRIcontrast agents, diagnostic imaging and monitoring, theranosticapplications, biocompatibility and biodegradability, remote controland manipulation, and responsive nanoparticles are the main factorsthat add to their novelty. In general, the amalgamation of nanoscalecharacteristics and magnetic properties presents a multitude ofopportunities for inventive medical applications, offering focused,effective, and least intrusive approaches to diagnosis and treatment.The sector is still investigating novel ways to increase the safety andefficacy of magnetic nanoparticles in nanomedicine. Moreover, itshould be noted that the creation of novel nanomedicines continuesto be a significant issue for academics, policymakers, and business.Collaboration among academics, industry, and regulatory bodiesis required to guarantee the security and efficacy of nanomedicineproducts. In the end, nanoparticles are predicted to be the futur-istic substance that will allow for excellence in every aspect ofnanomedicine. The main target of this article is to provide basicdetails about magnetic nanoparticles and the characteristics of theseparticles in biomedical applications. The features of these nanopar-ticles in medication delivery and their numerous uses have receivedextra focus in the study. It seeks to summarize current advancementsin MNPs for medical applications and examine the possibilities ofMNPs in tumor therapeutic applications in addition.ACKNOWLEDGMENTSThis study was sponsored by Prince Sattam Bin AbdulazizUniversity via Project No. 2023/RV/02.APL Mater. 12, 010601 (2024); doi: 10.1063/5.0191034 12, 010601-11© Author(s) 2024 31 January 2024 17:27:13https://pubs.aip.org/aip/apmAPL Materials REVIEW pubs.aip.org/aip/apmAUTHOR DECLARATIONSConflict of InterestThe authors have no conflicts to disclose.Ethical approvalThis article does not contain any studies with human partici-pants performed by the authors.Author ContributionsMahmoud M Selim: Conceptualization (equal); Data curation(equal); Formal analysis (equal); Funding acquisition (lead); Investi-gation (equal); Methodology (equal); Project administration (equal);Resources (lead); Writing – original draft (equal); Writing – review& editing (equal). Sherif El-Safty: Conceptualization (equal); Datacuration (equal); Formal analysis (equal); Methodology (equal);Validation (equal); Writing – original draft (equal); Writing –review & editing (equal). Abdelouahed Tounsi: Conceptualization(equal); Data curation (equal); Formal analysis (equal); Investiga-tion (equal); Methodology (equal); Resources (equal); Validation(equal); Writing – original draft (equal); Writing – review & edit-ing (equal). Mohamed Shenashen: Data curation (equal); Formalanalysis (equal); Investigation (equal); Methodology (equal); Valida-tion (equal); Visualization (equal); Writing – original draft (equal);Writing – review & editing (equal).DATA AVAILABILITYData sharing is not applicable to this article as no new data werecreated or analyzed in this study.REFERENCES1M. Hepel, “Magnetic nanoparticles for nanomedicine,” Magnetochemistry 6(1),3–17 (2020).2O. Hosu, M. Tertis, and C. Cristea, “Implication of magnetic nanoparticles incancer detection, screening and treatment,” Magnetochemistry 5(4), 55 (2019).3H. Lu, J. Wang, T. Wang, J. Zhong, Y. Bao, and H. Hao, “Recent progress onnanostructures for drug delivery applications,” J. Nanomater. 2016, 1.4E. Calzoni, A. Cesaretti, A. Polchi, A. Di Michele, B. Tancini, and C. Emiliani,“Biocompatible polymer nanoparticles for drug delivery applications in cancerand neurodegenerative disorder therapies,” J. Funct. Biomater. 10(1), 4 (2019).5J.-W. Rhee and J. C. Wu, “Advances in nanotechnology for the management ofcoronary artery disease,” Trends Cardiovasc. Med. 23(2), 39–45 (2013).6A. Wicki, D. Witzigmann, V. Balasubramanian, and J. Huwyler, “Nanomedicinein cancer therapy: Challenges, opportunities, and clinical applications,”J. Controlled Release 200, 138–157 (2015).7C. Comanescu, “Magnetic nanoparticles: Current advances in nanomedicine,drug delivery and MRI,” Chemistry 4(3), 872–930 (2022).8J. K. Patra et al., “Nano based drug delivery systems: Recent developments andfuture prospects,” J. Nanobiotechnol. 16(1), 71 (2018).9J. F. Liu et al., “Use of oppositely polarized external magnets to improve the accu-mulation and penetration of magnetic nanocarriers into solid tumors,” ACS Nano14(1), 142–152 (2019).10S. Gul, S. B. Khan, I. U. Rehman, M. A. Khan, and M. Khan, “A comprehensivereview of magnetic nanomaterials modern day theranostics,” Front. Mater. 6, 179(2019).11X. Li et al., “Current investigations into magnetic nanoparticles for biomedicalapplications,” J. Biomed. Mater. Res., Part A 104(5), 1285–1296 (2016).12M. Amiri, M. Salavati-Niasari, and A. Akbari, “Magnetic nanocarriers: Evolu-tion of spinel ferrites for medical applications,” Adv Colloid Interface Sci. 265,29–44 (2019).13M. Bilal, Y. Zhao, T. Rasheed, and H. M. Iqbal, “Magnetic nanoparticles as ver-satile carriers for enzymes immobilization: A review,” Int. J. Biol. Macromol. 120,2530–2544 (2018).14K. N. Clayton, J. W. Salameh, S. T. Wereley, and T. L. Kinzer-Ursem, “Physicalcharacterization of nanoparticle size and surface modification using particlescattering diffusometry,” Biomicrofluidics 10(5), 054107 (2016).15A. Santos, F. Veiga, and A. Figueiras, “Dendrimers as pharmaceutical excipients:Synthesis, properties, toxicity and biomedical applications,” Materials 13(1), 65(2019).16V. F. Cardoso, A. Francesko, C. Ribeiro, M. Bañobre-López, Martins, andS. Lanceros-Mendez, “Advances in magnetic nanoparticles for biomedicalapplications,” Adv. Healthcare Mater. 7(5), 1700845 (2018).17B. Cai et al., “Autofluorescent gelatin nanoparticles as imaging probes to moni-tor matrix metalloproteinase metabolism of cancer cells,” J. Biomed. Mater. Res.,Part A 104(11), 2854–2860 (2016).18M. Yaylaci, M. Abanoz, E. U. Yaylaci, H. Ölmez, D. M. Sekban, and A. Birinci,“Evaluation of the contact problem of functionally graded layer resting on rigidfoundation pressed via rigid punch by analytical and numerical (FEM and MLP)methods,” Arch. Appl. Mech. 92, 1953–1971 (2022).19M. Yaylaci, B. S. Sabano, M. E. Özdemir, and A. Birinci, “Solving the contactproblem of functionally graded layers resting on a HP and pressed with a uni-formly distributed load by analytical and numerical methods,” Struct. Eng. Mech.82(3), 401–416 (2022).20M. Turan, E. Uzun Yaylaci, and M. Yaylaci, “Free vibration and buckling offunctionally graded porous beams using analytical, finite element, and artificialneural network methods,” Arch. Appl. Mech. 93, 1351–1372 (2023).21E. U. Yaylaci, E. Oner, M. Yaylaci, M. E. Ozdemir, A. Abushattal, and A. Birinci,“Application of artificial neural networks in the analysis of the continuous contactproblem,” Struct. Eng. Mech. 84(1), 35–48 (2022).22M. Yaylaci, M. Abanoz, E. U. Yaylaci, M. E. Ozdemir, S. Ozturk, and H. Sesli,“Vibration and buckling analyses of FGM beam with edge crack: Finite elementand multilayer perceptron methods,” Steel Compos. Struct. 46(4), 565–575 (2023).23M. E. Özdemir and M. Yaylaci, “Research of the impact of material and flowproperties on fluid-structure interaction in cage systems,” Wind Struct. 36(1),31–40 (2023).24G. Adıyaman, E. Öner, M. Yaylaci, and A. Birinci, “A study on the contact prob-lem of a layer consisting of functionally graded material (FGM) in the presence ofbody force,” Struct. Eng. Mech. 82(3), 401–416 (2022); , J. Mech. Mater. Struct.18(1), 125–141 (2023).25M. Yaylaci, “Simulate of edge and an internal crack problem and estimationof stress intensity factor through finite element method,” Adv. Nano Res. 12(4),405–414 (2022).26M. Yaylaci, E. U. Yaylaci, M. E. Ozdemir, A. Sevil, and S. Ozturk,“Implementation of finite element and artificial neural network methods to ana-lyze the contact problem of a functionally graded layer containing crack,” SteelCompos. Struct. 45(4), 501–511 (2022).27M. Yaylaci, “The investigation crack problem through numerical analysis,”Struct. Eng. Mech. 57(6), 1143–1156 (2016).28M. Yaylacı, M. Abanoz, E. U. Yaylaci, H. Ölmez, D. M. Sekban, and A. Birinci,“The contact problem of the functionally graded layer resting on rigid foundationpressed via rigid punch,” Steel Compos. Struct. 43(5), 661–672 (2022).29E. Öner, B. Şengül Şabano, E. Uzun Yaylacı, G. Adıyaman, M. Yaylaci, andA. Birinci, “On the plane receding contact between two functionally graded lay-ers using computational, finite element and artificial neural network methods,”ZAMM - J. Appl. Math. Mech./Z. Angew. Math. Mech. 102(2), e202100287 (2022).30M. Yaylaci, M. Yayli, E. U. Yaylaci, H. Ölmez, and A. Birinci, “Analyzing thecontact problem of a functionally graded layer resting on an elastic half plane withtheory of elasticity, finite element method and multilayer perceptron,” Struct. Eng.Mech. 78(5), 585–597 (2021).31S. E. Sandler, B. Fellows, and O. T. Mefford, “Best practices for characteriza-tion of magnetic nanoparticles for biomedical applications,” Anal. Chem. 91(22),14159–14169 (2019).APL Mater. 12, 010601 (2024); doi: 10.1063/5.0191034 12, 010601-12© Author(s) 2024 31 January 2024 17:27:13https://pubs.aip.org/aip/apmhttps://doi.org/10.3390/magnetochemistry6010003https://doi.org/10.3390/magnetochemistry5040055https://doi.org/10.1155/2016/5762431https://doi.org/10.3390/jfb10010004https://doi.org/10.1016/j.tcm.2012.08.009https://doi.org/10.1016/j.jconrel.2014.12.030https://doi.org/10.3390/chemistry4030063https://doi.org/10.1186/s12951-018-0392-8https://doi.org/10.1021/acsnano.9b05660https://doi.org/10.3389/fmats.2019.00179https://doi.org/10.1002/jbm.a.35654https://doi.org/10.1016/j.cis.2019.01.003https://doi.org/10.1016/j.ijbiomac.2018.09.025https://doi.org/10.1063/1.4962992https://doi.org/10.3390/ma13010065https://doi.org/10.1002/adhm.201700845https://doi.org/10.1002/jbm.a.35823https://doi.org/10.1002/jbm.a.35823https://doi.org/10.1007/s00419-022-02159-5https://doi.org/10.12989/sem.2022.82.3.401https://doi.org/10.1007/s00419-022-02332-whttps://doi.org/10.12989/SEM.2022.84.1.035https://doi.org/10.12989/scs.2023.46.4.565https://doi.org/10.12989/was.2023.36.1.031https://doi.org/10.2140/jomms.2023.18.125https://doi.org/10.12989/anr.2022.12.4.405https://doi.org/10.12989/scs.2022.45.4.501https://doi.org/10.12989/scs.2022.45.4.501https://doi.org/10.12989/sem.2016.57.6.1143https://doi.org/10.12989/scs.2022.43.5.661https://doi.org/10.1002/zamm.202100287https://doi.org/10.12989/sem.2021.78.5.585https://doi.org/10.12989/sem.2021.78.5.585https://doi.org/10.1021/acs.analchem.9b03518APL Materials REVIEW pubs.aip.org/aip/apm32M. A. Shevtsov et al., “Detection of experimental myocardium infarctionin rats by MRI using heat shock protein 70 conjugated superparamagneticiron oxide nanoparticle,” Nanomed. Nanotechnol. Biol. Med. 12(3), 611–621(2016).33R. Dinali, A. Ebrahiminezhad, M. Manley-Harris, Y. Ghasemi, and A. Berenjian,“Iron oxide nanoparticles in modern microbiology and biotechnology,” Crit. Rev.Microbiol. 43(4), 493–507 (2017).34T. H. Shin et al., “Silica-coated magnetic nanoparticles decrease human bonemarrow-derived mesenchymal stem cell migratory activity by reducing membranefluidity and impairing focal adhesion,” Nanomaterials 9(10), 1475 (2019).35H. Hou, C. Wang, K. Nan, W. R. Freeman, M. J. Sailor, and L. Cheng,“Controlled release of dexamethasone from an intravitreal delivery systemusing porous silicon dioxide,” Invest. Opthalmology Visual Sci. 57(2), 557–566(2016).36H. Akbaba, U. Karagöz, Y. Selamet, and A. G. Kantarcı, “Synthesis andcharacterization of cationic lipid coated magnetic nanoparticles using multipleemulsions as microreactors,” J. Magn. Magn. Mater. 426, 518–524 (2017).37R. R. Oliveira et al., “Triggered release of paclitaxel from magnetic solidlipid nanoparticles by magnetic hyperthermia,” Mater. Sci. Eng.: C 92, 547–553(2018).38J. Alonso et al., “Superparamagnetic nanoparticles encapsulated in lipid vesi-cles for advanced magnetic hyperthermia and biodetection,” J. Appl. Phys. 119(8),083904 (2016).39M. Albini et al., “Movement of giant lipid vesicles induced by millimeterwave radiation change when they contain magnetic nanoparticles,” Drug DeliveryTransl. Res. 9, 131–143 (2019).40M. Zhang, J. Qiao, and L. Qi, “Dual-functional polymer-modified magneticnanoparticles for isolation of lysozyme,” Anal. Chim. Acta 1035, 70–76 (2018).41A. R. Chowdhuri, T. Singh, S. K. Ghosh, and S. K. Sahu, “Carbon Dots embed-ded magnetic nanoparticles @chitosan @metal organic framework as a nanoprobefor pH sensitive targeted anticancer drug delivery,” ACS Appl. Mater. Interfaces8(26), 16573–16583 (2016).42G. Kandasamy and D. Maity, “Recent advances in superparamagnetic iron oxidenanoparticles (SPIONs) for in vitro and in vivo cancer nanotheranostics,” Int. J.Pharm. 496(2), 191–218 (2015).43S. Talluri and R. R. Malla, “Superparamagnetic iron oxide nanoparticles (SPI-ONs) for diagnosis and treatment of breast, ovarian and cervical cancers,” Curr.Drug Metab. 20(12), 942–945 (2020).44J. Chan, M. S. Cheung, R. G. Gibbs, and K. K. Bhakoo, “MRI detection ofendothelial cell inflammation using targeted superparamagnetic particles of ironoxide (SPIO),” Clin. Transl. Med. 6(1), 1–8 (2017).45M. Dalmartello et al., “European cancer mortality predictions for the year 2022with focus on ovarian cancer,” Ann. Oncol. 33(3), 330–339 (2022).46T. I. Shabatina, O. I. Vernaya, V. P. Shabatin, and M. Y. Melnikov, “Magneticnanoparticles for biomedical purposes: Modern trends and prospects,” Magneto-chemistry 6(3), 30 (2020).47C. T. Nguyen, C. R. Kim, T. H. Le, K. Koo, and C. H. Hwang, “Magneticallyguided targeted delivery of erythropoietin using magnetic nanoparticles: Proof ofconcept,” Medicine 99(19), e19972 (2020).48B. L. Ferreira, F. Martel, C. Silva, T. Santos, and A. Daniel-da-Silva,“Nanostructured functionalized magnetic platforms for the sustained delivery ofcisplatin: Synthesis, characterization and in vitro cytotoxicity evaluation,” J. Inorg.Biochem. 213, 111258 (2020).49M. Schroffenegger et al., “Polymer topology determines the formation of proteincorona on core–shell nanoparticles,” ACS Nano 14(10), 12708–12718 (2020).50S. Saifullah, I. Ali, M. Kawish, R. M. El-Shabasy, L. Chen, and H. R. El-Seedi,“Surface functionalized magnetic nanoparticles for targeted cancer therapy anddiagnosis,” in Metal Nanoparticles for Drug Delivery and Diagnostic Applications(Elsevier, 2020), pp. 215–236.51M. Dabaghi and I. Hilger, “Magnetic nanoparticles behavior in biologicalsolutions; the impact of clustering tendency on sedimentation velocity and celluptake,” Materials 13(7), 1644 (2020).52F. Vurro et al., “Improving the cellular uptake of biomimetic magneticnanoparticles,” Nanomaterials 11(3), 766 (2021).53M. Gharagozloua, “NiFe2O4@ SiO2@ HKUST-1 as novel magnetic metal-organic framework nanocomposites for the curcumin adsorption,” J. Nanostruct.12(2), 455–473 (2022).54S. Ayyanaar, R. Bhaskar, S. Esthar, M. Vadivel, J. Rajesh, and G. Rajagopal,“Design and development of 5-fluorouracil loaded biodegradable magnetic micro-spheres as site-specific drug delivery vehicle for cancer therapy,” J. Magn. Magn.Mater. 546, 168853 (2022).55S. Talukdar, P. Saha, and K. Mandal, “Folate modified zinc ferrite nano-hollowspheres for drug delivery and intrinsic fluorescence,” AIP Conf. Proc. 2020,030131.56S. Al-Musawi, S. Albukhaty, H. Al-Karagoly, G. M. Sulaiman, M. S. Jabir, andH. Naderi-Manesh, “Dextran-coated superparamagnetic nanoparticles modifiedwith folate for targeted drug delivery of camptothecin,” Adv. Nat. Sci.: Nanosci.Nanotechnol. 11(4), 045009 (2020).57J. Sadhasivam and A. Sugumaran, “Magnetic nanocarriers: Emerging tool forthe effective targeted treatment of lung cancer,” J. Drug Delivery Sci. Technol. 55,101493 (2020).58H. Derakhshankhah et al., “A bio-inspired gelatin-based pH- and thermal-sensitive magnetic hydrogel for in vitro chemo/hyperthermia treatment of breastcancer cells,” J. Appl. Polym. Sci. 138(24), 50578 (2021).59L. P. Ferreira et al., “Assisted synthesis of coated iron oxide nanoparticles formagnetic hyperthermia,” Nanomaterials 12(11), 1870 (2022).60R. Weeber, P. Kreissl, and C. Holm, “Magnetic field controlled behavior ofmagnetic gels studied using particle-based simulations,” Phys. Sci. Rev. 8, 1465(2021).61C. S. Stoicescu, D. Culita, N. Stanica, F. Papa, R. N. State, and G. Munteanu,“Temperature programmed reduction of a core-shell synthetic magnetite: Depen-dence on the heating rate of the reduction mechanism,” Thermochim. Acta 709,179146 (2022).62F. Bruno et al., “Advanced magnetic resonance imaging (MRI) techniques:Technical principles and applications in nanomedicine,” Cancers 14(7), 1626(2022).63H. Zhou et al., “Hypoxia-triggered self-assembly of ultrasmall iron oxidenanoparticles to amplify the imaging signal of a tumor,” J. Am. Chem. Soc. 143(4),1846–1853 (2021).64W. J. Han, J. H. Lee, J.-K. Lee, and H. J. Choi, “Remote-controllable,tough, ultrastretchable, and magneto-sensitive nanocomposite hydrogels withhomogeneous nanoparticle dispersion as biomedical actuators, and their tunedstructure, properties, and performances,” Composites, Part B 236, 109802(2022).65M. E. Maffei, “Magnetic fields and cancer: Epidemiology, cellular biology, andtheranostics,” Int. J. Mol. Sci. 23(3), 1339 (2022).66S. Majee and G. C. Shit, “Modeling and simulation of blood flow with magneticnanoparticles as carrier for targeted drug delivery in the stenosed artery,” Eur. J.Mech.-B/Fluids 83, 42–57 (2020).67D. Zahn et al., “Investigation of magnetically driven passage of magneticnanoparticles through eye tissues for magnetic drug targeting,” Nanotechnology31(49), 495101 (2020).68M. Forouzandehmehr, I. Ghoytasi, A. Shamloo, and S. Ghosi, “Particles in coro-nary circulation: A review on modelling for drug carrier design,” Mater. Des. 216,110511 (2022).69M. Jafarzadeh, E. Soleimani, H. Sepahvand, and R. Adnan, “Synthesis and char-acterization of fluconazole-functionalized magnetic nanoparticles as a catalyst forthe synthesis of 3-aryl and 3-amino-imidazo[1,2-a]pyridines,” RSC Adv. 5(53),42744–42753 (2015).70A. G. Ranjbary, G. K. Saleh, M. Azimi, F. Karimian, J. Mehrzad, and J. Zohdi,“Superparamagnetic iron oxide nanoparticles induce apoptosis in HT-29 cells bystimulating oxidative stress and damaging DNA,” Biol. Trace Elem. Res. 201(3),1163–1173 (2023).71H. M. Abdel-Mageed, N. Z. AbuelEzz, R. A. Radwan, and S. A. Mohamed,“Nanoparticles in nanomedicine: A comprehensive updated review on currentstatus, challenges and emerging opportunities,” J. Microencapsulation 38(6),414–436 (2021).72S. Hadiya, R. Radwan, M. Zakaria, T. El-Sherif, M. A. Hamad, and M. Elsabahy,“Nanoparticles integrating natural and synthetic polymers for in vivo insulindelivery,” Pharm. Dev. Technol. 26(1), 30–40 (2021).APL Mater. 12, 010601 (2024); doi: 10.1063/5.0191034 12, 010601-13© Author(s) 2024 31 January 2024 17:27:13https://pubs.aip.org/aip/apmhttps://doi.org/10.1016/j.nano.2015.10.017https://doi.org/10.1080/1040841X.2016.1267708https://doi.org/10.1080/1040841X.2016.1267708https://doi.org/10.3390/nano9101475https://doi.org/10.1167/iovs.15-18559https://doi.org/10.1016/j.jmmm.2016.11.126https://doi.org/10.1016/j.msec.2018.07.011https://doi.org/10.1063/1.4942618https://doi.org/10.1007/s13346-018-0572-yhttps://doi.org/10.1007/s13346-018-0572-yhttps://doi.org/10.1016/j.aca.2018.07.019https://doi.org/10.1021/acsami.6b03988https://doi.org/10.1016/j.ijpharm.2015.10.058https://doi.org/10.1016/j.ijpharm.2015.10.058https://doi.org/10.2174/1389200220666191016124958https://doi.org/10.2174/1389200220666191016124958https://doi.org/10.1186/s40169-016-0134-1https://doi.org/10.1016/j.annonc.2021.12.007https://doi.org/10.3390/magnetochemistry6030030https://doi.org/10.3390/magnetochemistry6030030https://doi.org/10.1097/md.0000000000019972https://doi.org/10.1016/j.jinorgbio.2020.111258https://doi.org/10.1016/j.jinorgbio.2020.111258https://doi.org/10.1021/acsnano.0c02358https://doi.org/10.3390/ma13071644https://doi.org/10.3390/nano11030766https://doi.org/10.22052/JNS.2022.02.020https://doi.org/10.1016/j.jmmm.2021.168853https://doi.org/10.1016/j.jmmm.2021.168853https://doi.org/10.1063/5.0017441https://doi.org/10.1088/2043-6254/abc75bhttps://doi.org/10.1088/2043-6254/abc75bhttps://doi.org/10.1016/j.jddst.2019.101493https://doi.org/10.1002/app.50578https://doi.org/10.3390/nano12111870https://doi.org/10.1515/psr-2019-0106https://doi.org/10.1016/j.tca.2022.179146https://doi.org/10.3390/cancers14071626https://doi.org/10.1021/jacs.0c10245https://doi.org/10.1016/j.compositesb.2022.109802https://doi.org/10.3390/ijms23031339https://doi.org/10.1016/j.euromechflu.2020.04.004https://doi.org/10.1016/j.euromechflu.2020.04.004https://doi.org/10.1088/1361-6528/abb0b4https://doi.org/10.1016/j.matdes.2022.110511https://doi.org/10.1039/C5RA05246Ghttps://doi.org/10.1007/s12011-022-03229-zhttps://doi.org/10.1080/02652048.2021.1942275https://doi.org/10.1080/10837450.2020.1832117APL Materials REVIEW pubs.aip.org/aip/apm73S. Doganay, A. Turgut, and L. Cetin, “Magnetic field dependent thermal con-ductivity measurements of magnetic nanofluids by 3ω method,” J. Magn. Magn.Mater. 474, 199–206 (2019).74K. Ali, Y. Javed, and Y. Jamil, “Size and shape control synthesis of ironoxide–based nanoparticles: Current status and future possibility,” in ComplexMagnetic Nanostructures (Springer Nature, 2017), pp. 39–81.75S. Tripathi, Development of Curcumin Loaded-Magnetic Iron Oxide Nanoparti-cles (Assumption University, 2015).76C. M. Hussain, Magnetic Nanomaterials for Environmental Analysis (RoyalSociety of Chemistry, 2016).77I. Corsi et al., “Environmentally sustainable and ecosafe polysaccharide-basedmaterials for water nano-treatment: An eco-design study,” Materials 11(7), 1228(2018).78N. V. S. Vallabani, S. Singh, and A. S. Karakoti, “Magnetic nanoparticles: Cur-rent trends and future aspects in diagnostics and nanomedicine,” CDM 20(6),457–472 (2019).79I. Molwitz, H. Ittrich, T. Knopp, T. Mummert, J. Salamon, C. Jung, G. Adam,and M. G. Kaul, “First magnetic particle imaging angiography in human-sizedorgans by employing a multimodal ex vivo pig kidney perfusion system,” Physiol.Meas. 40, 105002 (2019).80N. Talebloo, M. Gudi, N. Robertson, and P. Wang, “Magnetic particle imaging:Current applications in biomedical research,” J. Magn. Reson. Imaging 51, 1659(2019).81C. Shasha, E. Teeman, and K. M. Krishnan, “Nanoparticle core size opti-mization for magnetic particle imaging,” Biomed. Phys. Eng. Express 5, 055010(2019).82E. Teeman C. Shasha, J. E. Evans, and K. M. Krishnan, “Intracellular dynam-ics of superparamagnetic iron oxide nanoparticles for magnetic particle imaging,”Nanoscale 11, 7771 (2019).83E. Y. Yu, M. Bishop, B. Zheng, R. M. Ferguson, A. P. Khandhar, S. J. Kemp,K. M. Krishnan, W. Goodwill, and S. M. Conolly, “Magnetic particle imaging: Anovel in vivo imaging platform for cancer detection,” Nano Lett. 17, 1648–1654(2017).84D. Bobo, K. J. Robinson, J. Islam, K. J. Thurecht, and S. R. Corrie, “Nanoparticle-based medicines: A review of FDA-approved materials and clinical trials to date,”Pharm. Res. 33, 2373–2387 (2016).APL Mater. 12, 010601 (2024); doi: 10.1063/5.0191034 12, 010601-14© Author(s) 2024 31 January 2024 17:27:13https://pubs.aip.org/aip/apmhttps://doi.org/10.1016/j.jmmm.2018.10.142https://doi.org/10.1016/j.jmmm.2018.10.142https://doi.org/10.3390/ma11071228https://doi.org/10.2174/1389200220666181122124458https://doi.org/10.1088/1361-6579/ab4436https://doi.org/10.1088/1361-6579/ab4436https://doi.org/10.1002/jmri.26875https://doi.org/10.1088/2057-1976/ab3972https://doi.org/10.1039/c9nr01395dhttps://doi.org/10.1021/acs.nanolett.6b04865https://doi.org/10.1007/s11095-016-1958-5